WEIGHT MANAGEMENT / TREATMENT INFORMATION
Understanding
your options.
Prescription treatment may form one part of weight-management care where it is clinically appropriate. The treatment considered will depend on factors including your health, medical and medication history, treatment goals, preferences and individual circumstances.
No single medicine is right for everyone. The information below is designed to help you understand some of the treatment options that may be discussed following an appropriate clinical assessment.
Mounjaro
Tirzepatide
Weekly injectionGIP + GLP-1
Read treatment informationWegovy
Semaglutide
Weekly injectionGLP-1
Read treatment informationWegovy Tablets
Semaglutide
Daily tabletGLP-1
Read treatment informationFoundayo
Orforglipron
Daily tabletGLP-1
Read treatment informationCOMPARE AT A GLANCE
The details, considered.
Administration and dose schedules. Suitability requires individual assessment.
| Consideration | Mounjaro | Wegovy Injection | Wegovy Tablets | Foundayo |
|---|---|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide | Semaglutide | Orforglipron |
| Format | Subcutaneous injection | Subcutaneous injection | Tablet | Tablet |
| Frequency | Once weekly | Once weekly | Once daily | Once daily |
| Main receptor activity | GIP + GLP-1 | GLP-1 | GLP-1 | GLP-1 |
| Initial dose | 2.5 mg weekly | 0.25 mg weekly | 1.5 mg daily | 0.8 mg daily |
| Escalation | At intervals of at least 4 weeks | Standard schedule usually escalates every 4 weeks | Usually monthly through the licensed dose steps | At intervals of at least 30 days |
| Administration | Weekly injection | Weekly injection | Empty stomach with specific fasting/water timing | Can be taken with or without food |
Mounjaro
- Active ingredient
- Tirzepatide
- Format
- Subcutaneous injection
- Frequency
- Once weekly
- Main receptor activity
- GIP + GLP-1
- Initial dose
- 2.5 mg weekly
- Escalation
- At intervals of at least 4 weeks
- Administration
- Weekly injection
Wegovy Injection
- Active ingredient
- Semaglutide
- Format
- Subcutaneous injection
- Frequency
- Once weekly
- Main receptor activity
- GLP-1
- Initial dose
- 0.25 mg weekly
- Escalation
- Standard schedule usually escalates every 4 weeks
- Administration
- Weekly injection
Wegovy Tablets
- Active ingredient
- Semaglutide
- Format
- Tablet
- Frequency
- Once daily
- Main receptor activity
- GLP-1
- Initial dose
- 1.5 mg daily
- Escalation
- Usually monthly through the licensed dose steps
- Administration
- Empty stomach with specific fasting/water timing
Foundayo
- Active ingredient
- Orforglipron
- Format
- Tablet
- Frequency
- Once daily
- Main receptor activity
- GLP-1
- Initial dose
- 0.8 mg daily
- Escalation
- At intervals of at least 30 days
- Administration
- Can be taken with or without food
The medicines differ in their active ingredients, how they are taken, dose schedules and other clinical considerations. Suitability is assessed individually rather than by selecting a medicine from a table.
Last reviewed: September 2026